Overview

  • Product name

    LFM-A13, BTK inhibitor
  • Description

    Selective BTK inhibitor
  • Biological description

    Selective Bruton's tyrosine kinase (BTK) inhibitor (IC50 = 2.5 μM). Also inhibits polio-like kinase (Plk1) (IC50 = 37.36 μM). Does not effect EGF receptor, insulin recptor, JAK-1 JAK-2, JAK-3, SYK or HCK (IC50 values are all >300 μM). Anticancer and antileukemic agent. Active in vivo.
  • Purity

    > 97%
  • CAS Number

    244240-24-2
  • Chemical structure

    Chemical Structure

Properties

References

This product has been referenced in:

  • Uckun FM  et al. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK). Bioorg Med Chem 15:800-14 (2007). Read more (PubMed: 17098432) »
  • Tibbles HE  et al. In vivo toxicity and antithrombotic profile of the oral formulation of the antileukemic agent, LFM-A13-F. Arzneimittelforschung 54:330-9 (2004). Read more (PubMed: 15281619) »
  • Vassilev A  et al. Bruton's tyrosine kinase as an inhibitor of the Fas/CD95 death-inducing signaling complex. J Biol Chem 274:1646-56 (1999). Read more (PubMed: 9880544) »

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab141575.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES, NOT FOR USE IN HUMANS"
For licensing inquiries, please contact partnerships@abcam.com

Sign up